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Rezumat
Celulele stem şi hepatocitele în terapia boliilor hepatice
În prezent, există un interes crescut a utilizării celulelor stem în terapia diferitor boli.
Celulele stem au capacitatea de a se devide pentru o perioadă indefinită de timp, de a se auto-
reînoi  şi  de  a  da  naştere  mai  multor  tipuri  de  celule.  Terapia  celulară poate  fi  definită ca
„utilizarea celulelor în restabilirea, menţinerea şi îmbunătăţirea funcţiilor ţesuturilor şi
organelor”. Acest articol de sinteză este adresat hepatocitelor, celulelor stem hepatice, inclusiv
originii lor, rolului acestora în regenerarea ficatului şi dezvoltarea fibrozei, şi folosirea lor
posibilă în tratarea bolii de ficat. Cele mai multe tulburări hepatice rezultă din disfuncţia
hepatocitelor, aici acordîndu-se un mare interes  transplantului de hepatocite izolate. În închiere,
hepatocitele izolate şi derivate trebuie să demonstreze activitatea normală fiziologică, anume în
funcţia de detoxificare şi metabolismul specific, ce se determină prin expresia genelor a
proteinelor prezente în hepatocitele adulte.
Summary
At present, there is growing interest in the therapeutic use of stem cells. A stem cell has the
ability to divide for indefinite periods of time, to self-renew and to give rise to many different
cell types. Cell therapy can be defined as «the use of living cells to restore, maintain or enhance
the function of tissues and organs». This review will address on hepatocytes, hepatic stem cells,
including their origin, their role in liver regeneration and fibrosis, and their possible use in the
treatment of liver disease. As most liver disorders result from hepatocyte dysfunction, there has
been great interest in transplantation of isolated hepatocytes. In summary, isolated and derived
hepatocytes should demonstrate drug metabolism and detoxification activity by both gene
expression and function, and they should express the hepatic transport proteins and transcription
factors present in mature hepatocytes.
Diseases of the liver impose a heavy burden on society and affect approximately 17% of the
world population [4]. Viral hepatitis, acute and chronicle, cirrhosis and hepatic cancer present a
very important medical and socio-economical problem in Republic of Moldova. More than
10000 people are infected with viral hepatitis every year [27, 28]. Cirrhosis is a progressive liver
disease  and  is  marked  by  the  gradual  destruction  of  liver  tissue  over  time.  Globally  the  main
causes of cirrhosis are hepatitis B, C and alcohol abuse. There is 79,2% of patients deaths with
digestive system diseases is cause of cirrhosis. Cirrhosis is one of the important and common
causes of death and mortality from cirrhosis have increased last 20 years in Moldova [27].
Despite the high incidence of liver diseases that result in liver dysfunction and failure,
current medical therapies are limited.
At the cirrhotic stage, liver disease is considered irreversible and the only solution is
orthotopic liver transplantation (OLT). Liver transplantation is considered to be the standard
treatment. Unfortunately, its extensive application is restricted by the limited availability of
donor  organs.  In  addition,  liver  transplantation  is  associated  with  significant  morbidity  and
mortality. However, the increasing shortage of donor organs restricts liver transplantation, life-
long dependence on immunosuppression and the poor outcome in patients not supported by liver
transplantation, there is obviously a demand for new strategies to treat lever disorders [28].
Cell  therapy  can  be  defined  as  «the  use  of  living  cells  to  restore,  maintain  or  enhance  the
function of tissues and organs» [1]. The use of isolated, viable cells has emerged as an
experimental therapeutic tool in the past decade, due to progress in cell biology and particularly
in techniques for the isolation and culture of cells derived from several organs and tissues.
However, experimental cell therapy has a longer tradition in hepatology, since it has been known
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for more than 30 years that isolated hepatocytes infused into the portal vein engraft into the liver
cords and express normal cell function. Such a therapeutic strategy was put forward as an
alternative to OLT, which requires major surgery and is limited by the availability of donors.
Indeed, it was shown that significant clinical results can be obtained with the transplantation of
isolated hepatocytes corresponding to as little as 1-5% of the total hepatocyte mass [2,3].
This review will address on hepatocytes, hepatic stem cells, including their origin, their role
in liver regeneration and fibrosis, and their possible use in the treatment of liver disease.
Mammalian liver development and hepatic induction
Embryonic  stem  cell  are  derived  from  the  undifferentiated  cell  of  the  epiblast,  which  give
rise to the three principal germ layers and their differentiated progeny through a process called
gastrulation [25, 29]. Of the three germ cell layers the endoderm gives rise to hepatic, pancreatic,
lung, and intestinal tissues in a process that is not well understood.
 Using a variety of techniques, it has now been shown that fibroblast growth factors (FGFs)
can substitute for cardiac mesoderm and bone morphogenic proteins (BMPs) can substitute for
the septum transversum mesenchyme to work in concert to induce the ventral endoderm to adopt
a hepatic fate [26]. Factors identified as proposed targets of FGF and BMP signaling include the
Foxa and Gata genes, which regulate the competence of foregut endoderm to respond to hepatic
inductive signals [29, 30]. In addition, the transcription factor hepatocyte nuclear factor-6
(HNF6) has been shown to play a critical role in the proper morphogenesis of both the intra- and
extra-hepatic biliary tree. The mechanism by which HNF6 regulates biliary tree development
also appears to involve the related transcription factor, hepatocyte nuclear factor-1 (HNF1) [20].
Hepatocytes and bile duct cells originate from a common precursor, the hepatoblast [24]. Notch
signaling promotes hepatoblast differentiation toward the biliary epithelial lineage, while HGF
promotes differentiation toward the hepatocyte lineage [22].
Physiological homeostasis of the liver
The normal liver contains hepatocytes, endothelioctyes, Kupffer cells, and hepatic stellate
cells. Hepatic stellate cells are the key fibrogenic cells. During hepatic fibrogenesis, hepatic
stellate cells undergo a response known as “activation,” which is the transition of quiescent cells
into myofibroblasts. Activated hepatic stellate cells are the critical source of extracellular matrix
in hepatic fibrosis [30].
Under physiological conditions, as few as one out of 2000–3000 hepatocytes divide to
maintain the physiological liver mass. Liver damage or loss of liver mass can however
extensively stimulate the regenerative capacity until the tissue mass has been restored by the
proliferation of mature parenchymal liver cells [8]. Up to 75% of surgically removed liver mass
can be regenerated within 1 week in rodents [5]. The newborn liver contains only diploid
hepatocytes but polyploidisation and binuclearity occurs rapidly after birth.
Fractionation of isolated adult rat hepatocytes based on cell density has yielded
subpopulations with “small” mononucleated hepatocytes and “large” hepatocytes with higher
ploidy. Hepatocytes with higher ploidy have been shown to reside predominantly in the
perivenous areas and to contain more DNA and to exhibit greater maturity. The “smaller”
mononucleated hepatocytes are located in the periportal areas, contain less DNA and exhibit
greater growth factor responsiveness [9, 28].
The “streaming liver hypothesis”, which suggests that the liver lobule is organised in a
similar way to the intestinal crypt by containing a stem cell pool arising form the periportal area
has, however, been disproved by the observation that nearly all hepatocytes proliferate as a
response to injury, regardless of location and ploidy [24].
Although mature hepatocytes and cholangiocytes represent the first and most important
resource for tissue repair, experimental data support the hypothesis that the liver also contains or
activates a stem cell compartment [17]. Today the origin of hepatic stem or precursor cells is still
a matter of debate.
Interestingly, oval cells express markers of Hematopoietic Stem Cells (HSCs), such as Thy-
1, CD34, CD45, Sca-1, c-Kit and flt-3 [12-16]. In particular, Thy-1 is a highly conserved protein.
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It has been found in the brain and in the hematopoietic system of rat, mouse and humans [16,
30]. It is also expressed on stem cells of fetal  liver and in bone marrow (BM)-derived cells. In
addition,  the  normal  adult  liver  contains  hematopoietic  cells  that  are  phenotypically  similar  to
cells present in the BM [30]. These observations originated the hypothesis that liver stem cells
may arise from a population resident in the BM. Also, experimental evidence suggests that liver
parenchymal cells can originate from a specific precursor cell compartment in the liver, from
pluripotent stem cells, from transdifferention of HSCs or cell fusion.
Hepatocyte isolation
As most liver disorders result from hepatocyte dysfunction, there has been great interest in
transplantation of isolated hepatocytes. However, their clinical application is also dependent on
the availability of good quality donor livers. To overcome the problem of limited donor organs
and to make hepatocytes available for other applications, several approaches to isolate and
propagate liver stem cells or progenitor cells have been developed.
Hepatocyte isolation from human livers is now universally performed with a “two-step”
collagenase procedure developed by Berry and Friend [28]. Originally developed for the
isolation of rat hepatocytes, this procedure has been modified by various laboratories for the
isolation of hepatocytes from sevreal animal species, including human  [3,4].
The procedure involves the initial perfusion of the liver with a warm (37◦C) divalent ion-free,
EGTA-containing, isotonic buffer (Step 1) to remove blood and to loosen cell–cell junctions,
followed by perfusion with a warm, isotonic, collagenase solution (Step 2) to dissociate the liver
parenchyma into single cells. In general, a higher amount of collagenase is required for the
isolation of hepatocytes from human livers than that required for rat livers. As collagenase is a
mixture  of  proteases,  its  composition  can  affect  its  effectiveness  in  the  dissociation  of  the
hepatocytes as well as its cytotoxicity. It is a common practice to evaluate multiple lots of
collagenase to select the one lot yielding the highest number of viable hepatocytes from a liver.
After digestion, the cells are harvested by low speed centrifugation. A density gradient such as
Percoll is commonly used to enrich for viable cells. The isolated cells can be used in suspension
for experiments requiring a relatively short time duration (hours), plated on tissue culture
surfaces pretreated with attachment substrates (e.g. collagen; Matrigel) for longer term studies,
or cryopreserved for future use [10].
The method of isolation of human hepatocytes from a human liver is by no means optimized.
Currently, a so called “good” yield of human hepatocytes from a human liver is approximately
10–30 billion viable cells when a whole liver is perfused. Using an approximation of 1.5 kg as an
average weight of a human liver, this leads to a yield of or approximately 7–20 million
hepatocytes per gram of liver (e.g. [5, 6, 29]), which is considerably less that the total number of
hepatocytes (approximately 300 billion) in the human liver. It is to be noted that the yield of
human hepatocytes (in terms of number of hepatocytes per gram liver) is in general higher from
smaller (e.g., 10 to 300 g) liver fragments then whole livers or lobes [24, 29].
Cryopreservation
Hepatocytes, especially human hepatocytes, are now routinely used after they are
cryopreserved [7, 8]. The general procedures for hepatocyte cryopreservation have not deviated
extensively from the original procedures [9]. Via the use of equipments to control freezing rates
(e.g. programmable control-rate freezer) and appropriate cryopreservation agents (e.g. dimethyl
sulfoxide), hepatocytes now can be stored in liquid nitrogen (lower than −150 ◦C) for an
extensively time period (years) with the retention of high viability and drug metabolizing
enzyme activity [7]. The most recent advancement of human hepatocyte cryopreservation is the
ability of the thawed hepatocytes to be plated as monolayer cultures (“plateable” hepatocytes)
[10,11].
Stem cell differentiation into hepotocytes
Methods for differentiating stem cells into hepatocytes can be separated into those that
involve spontaneous formation of liver-like cells and those involving directed differentiation [17,
22].
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Spontaneous differentiation involves  formation  of  EBs,  plating  of  ES  cells  on  an  adherent
matrix as a monolayer, or following transplantation into an hepatic environment [22,29]
Directed differentiation usually involves addition of growth factors and cytokines to cells in
vitro on extracellular matrices. Combinations of these techniques, involving both formation of
EBs with expansion in growth factors and/or co-culture with cells supplying additional factors,
have also been successful [29]. In addition, culture in sodium butyrate, a histone deacetylase
inhibitor, leads to an increase in the number of cells expressing mature hepatocyte-specific
genes.
Selection of hepatocyte-like cells based on the use of liver-specific promoters that drive
reporter gene expression has been a relatively successful strategy for selecting a homogeneous
population of cells with hepatic characteristics [22,29]
In the majority of settings, the resultant cells have morphological features similar to those of
primary hepatocytes and most of the cells express liver-associated proteins. Whether such cells
have the functional characteristics of a mature liver cell will require a more comprehensive
analysis.
To adequately assess the extent to which in vitro differentiation of stem cells has been
effective, it will be important to clearly demonstrate cellular characteristics and activities that
can only be performed by primary hepatocytes.
1. Gene expression by differentiated “hepatocyte-like” cells should be compared to the gene
expression profile of human fetal and/or mature liver cells [29];
2. Evidence of basal and inducible CYP450 isoform function should be assessed [23,29];
3. Metabolism of xenobiotics or other endogenous substances (hormones and ammonia)
should be determined [21,29];
4. Synthesis and/or secretion of the following should be performed: albumin, clotting factors,
complement, transporter proteins, bile acids, and lipids and lipoproteins. [29];
5. Evidence of restoration of liver function in appropriate animal models, or evidence of
repopulation of the liver by derived “hepatocytes” should be examined.
In summary, derived hepatocytes should demonstrate drug metabolism and detoxification
activity by both gene expression and function, and they should express the hepatic transport
proteins and transcription factors present in mature hepatocytes.
The procedure seems relatively safe, provided portal pressure and/or portal flow are
monitored during cell infusion in order to prevent vascular thrombosis [30]. Hepatocyte
transplantation has recently been used as an alternative to OLT in patients with liver-based
congenital metabolic disorders, such as Crigler-Najjar disease, α-1-antitrypsin deficiency
glycogen storage disease type Ia,10 ornithine transcarbamoylase deficiency and the deficiency of
factor VII [7, 8, 9] The role of hepatocyte transplantation in the treatment of acute and chronic
liver disease is less clear due to difficulty in organizing large-scale clinical trials.
Indeed, the main factor limiting the practice of hepatocyte transplantation is again the
availability  of  liver  grafts  for  cell  isolation.  Moreover,  the  metabolic  effects  of  cell
transplantation seem to be fading with time, a problem which can partially be solved by repeated
hepatocyte infusions but which probably indicates the progressive loss of the terminally-
differentiated exogenous cells. In theory, both problems could be solved by replacing the
hepatocyte with stem or precursor cells, provided they can be isolated from a more affordable
source [11, 12].
At present, there is growing interest in the therapeutic use of stem cells [28]. A stem cell has
the ability to divide for indefinite periods of time, to self-renew and to give rise to many different
cell types. Embryonic stem cells originate from the inner cell mass of the mammalian blastocyst
and are totipotent. Adult stem cells are more specialized, being committed to give rise to cells
with a particular function within their own specific tissue or organ. Precursor/progenitor cells are
defined as cells rapidly dividing and already partially determined towards specific differentiation
pathways [28-30].
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However, experimental evidence suggests that some adult stem cells are able to develop into
different types of specialized cells (a process also known as transdifferentiation), depending on
the microenvironment where they are homed, including the liver.
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Summary
Ways to improve treatment outcomes in suppurated liver echinococcus
We analyzed the treatment outcomes in 63 patients with suppurated liver echinococcus
and concluded that intraparenchymal cysts suppurate more often due to compression and
communication with the bile ducts. The medication adjustment must be done before surgery. The
volume of surgery must be appreciated during the operation in dependence of localization of the
cyst and patients condition. We recommend application of the immunotentiation of the liver
parenchyma with the mononuclear cells to ameliorate the reparative properties.
Rezumat
Noi am analizat rezultatele tratamentului a 63 de bolnavi cu echinococoza supurată a
ficatului şi am ajuns la concluzie că mai des supurează chisturile intraparenchimatoase din cauza
compresiei şi comunicării cu ducturile biliare. Înainte de operaţie trebuie de efectuat corecţia
medicamentoasă. Volumul operaţie trebuie de apreciat intraoperator în dependenţă de localizarea
chistului şi stării pacientului. Noi recomandăm aplicarea imunostimulării parenchimului ficatului
cu celulele mononucleare pentru ameliorarea proprietăţilor reparative.
Actualitate
Echinococoza, fiind o patologie regională pentru Moldova, este o problemă medicală
serioasă. Deşi stabilirea diagnosticului de echinococoza hepatică în prezent nu este dificilă,
stadiile primare asimptomatice duc la adresarea tardivă a pacienţilor. Majoritatea operaţiilor se
efectuează când cea mai mare parte a parenchimului ficatului este înlocuită cu chist parazitar şi
